Waters Corp
WATWaters Corporation (WAT) is a global provider of analytical technologies, primarily serving the life sciences, pharmaceutical, and biopharmaceutical markets. Founded in 1958, the company specializes in laboratory instruments, software, and consumables used in scientific research, quality testing, and drug development. Waters is known for its chromatography and mass spectrometry systems, which enable precise and accurate analysis of complex samples.
Company News
Fenimore Asset Management completely sold its entire 243,780 shares of Waters Corporation, valued at $85.09 million, representing a full exit from the position during Q3 2025. The sale reflects a strategic portfolio shift amid challenging market conditions for laboratory instrumentation stocks.
Healthcare merger and acquisition activity rose 7% in Q3 2025, with 532 deals announced. Physician Medical Groups led with 130 deals, while total deal value reached $63.8 billion, a 111% increase from the previous quarter.
The global chromatography market in pharmaceuticals and biotechnology is projected to grow from $13.3 billion in 2025 to $19.8 billion by 2030, with an 8.4% CAGR, driven by rising biopharmaceutical innovations, regulatory standards, and demand for generics and biosimilars.
Waters (WAT) reported a 4.3% decline in revenue and a 6.1% decrease in EPS for Q2 2024 compared to the same period last year. The company's performance was mixed across its divisions, with the Water division and TA division seeing declines, while the service business saw growth.
